What do systematic reviews say?

Orexin antagonists vs placebo

The review found no eligible studies for this question.

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Orexin antagonists vs placebo

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 274 participants
  Moderate

Melatonin vs placebo

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Melatonin vs placebo

Melatonin showed no clear difference in reporting ≥ 1 adverse event compared with placebo (low certainty).

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  RR 1.07 [0.86, 1.33]
  1 study · 151 participants
  Low

Melatonin vs placebo

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 162 participants
  Low

Melatonin vs placebo

The review found no eligible studies for this question.

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Melatonin vs placebo

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Low

Trazodone vs placebo

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Low

Trazodone vs placebo

The review found no eligible studies for this question.

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Δ9‐Tetrahydrocannabinol preparation vs placebo

Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants abstinent at end of treatment compared with placebo (moderate certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 0.98 [0.64, 1.52]
  3 studies · 305 participants
  Moderate

Mixed action antidepressant vs placebo

Mixed action antidepressant showed no clear difference in participants experiencing adverse effects compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.55, 1.55]
  1 study · 76 participants
  Low

Mixed action antidepressant vs placebo

Mixed action antidepressant showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 1.44 [0.11, 18.9]
  2 studies · 179 participants
  Low

Mixed action antidepressant vs placebo

Mixed action antidepressant showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.71, 1.21]
  2 studies · 169 participants
  Low

Anticonvulsants and mood stabilisers vs placebo

It is very uncertain whether anticonvulsants and mood stabilisers changes participants abstinent at end of treatment compared with placebo (very low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 1.14 [0.64, 2.04]
  2 studies · 48 participants
  Very low

Anticonvulsants and mood stabilisers vs placebo

It is very uncertain whether anticonvulsants and mood stabilisers changes participants withdrawn due to adverse effects compared with placebo (very low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 3.67 [0.41, 32.69]
  2 studies · 116 participants
  Very low

Anticonvulsants and mood stabilisers vs placebo

Anticonvulsants and mood stabilisers may leads to lower completion of scheduled treatment compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 0.66 [0.47, 0.92]
  3 studies · 141 participants
  Low

Buspirone vs placebo

Buspirone showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 1.98 [0.62, 6.33]
  1 study · 175 participants
  Low

Buspirone vs placebo

Buspirone showed no clear difference in participants experiencing adverse effects compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 1.14 [1, 1.29]
  2 studies · 225 participants
  Low

Buspirone vs placebo

Buspirone showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 0.63 [0.15, 2.6]
  2 studies · 225 participants
  Low

Buspirone vs placebo

Buspirone showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).

• Pharmacotherapies for cannabis dependence 2019 · Cochrane Headline outcomes only
  RR 0.96 [0.74, 1.23]
  2 studies · 225 participants
  Low